147 related articles for article (PubMed ID: 15117734)
21. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.
Pennacchio LA; Olivier M; Hubacek JA; Krauss RM; Rubin EM; Cohen JC
Hum Mol Genet; 2002 Nov; 11(24):3031-8. PubMed ID: 12417524
[TBL] [Abstract][Full Text] [Related]
22. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.
Dallongeville J; Cottel D; Montaye M; Codron V; Amouyel P; Helbecque N
Int J Cardiol; 2006 Jan; 106(2):152-6. PubMed ID: 16321685
[TBL] [Abstract][Full Text] [Related]
23. Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.
Talmud PJ
Atherosclerosis; 2007 Oct; 194(2):287-92. PubMed ID: 17222847
[TBL] [Abstract][Full Text] [Related]
24. APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese.
Chien KL; Fang WH; Wen HC; Lin HP; Lin YL; Lin SW; Wu JH; Kao JT
Clin Chim Acta; 2008 Apr; 390(1-2):56-62. PubMed ID: 18206649
[TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein A5 and hypertriglyceridemia.
Charlton-Menys V; Durrington PN
Clin Chem; 2005 Feb; 51(2):295-7. PubMed ID: 15681559
[No Abstract] [Full Text] [Related]
27. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
Grosskopf I; Baroukh N; Lee SJ; Kamari Y; Harats D; Rubin EM; Pennacchio LA; Cooper AD
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2573-9. PubMed ID: 16166565
[TBL] [Abstract][Full Text] [Related]
28. Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients.
Pruneta-Deloche V; Ponsin G; Groisne L; Fruchart-Najib J; Lagarde M; Moulin P
Atherosclerosis; 2005 Aug; 181(2):403-5. PubMed ID: 16039297
[TBL] [Abstract][Full Text] [Related]
29. Give me A5 for lipoprotein hydrolysis!
Merkel M; Heeren J
J Clin Invest; 2005 Oct; 115(10):2694-6. PubMed ID: 16200205
[TBL] [Abstract][Full Text] [Related]
30. Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons.
Wang QF; Liu X; O'Connell J; Peng Z; Krauss RM; Rainwater DL; VandeBerg JL; Rubin EM; Cheng JF; Pennacchio LA
Hum Mol Genet; 2004 May; 13(10):1049-56. PubMed ID: 15044382
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha.
Genoux A; Dehondt H; Helleboid-Chapman A; Duhem C; Hum DW; Martin G; Pennacchio LA; Staels B; Fruchart-Najib J; Fruchart JC
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1186-92. PubMed ID: 15790933
[TBL] [Abstract][Full Text] [Related]
32. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.
Ito Y; Azrolan N; O'Connell A; Walsh A; Breslow JL
Science; 1990 Aug; 249(4970):790-3. PubMed ID: 2167514
[TBL] [Abstract][Full Text] [Related]
33. The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
Martinelli N; Trabetti E; Bassi A; Girelli D; Friso S; Pizzolo F; Sandri M; Malerba G; Pignatti PF; Corrocher R; Olivieri O
Atherosclerosis; 2007 Apr; 191(2):409-17. PubMed ID: 16682041
[TBL] [Abstract][Full Text] [Related]
34. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction.
Hubacek JA; Skodová Z; Adámková V; Lánská V; Poledne R
Clin Genet; 2004 Feb; 65(2):126-30. PubMed ID: 14984471
[TBL] [Abstract][Full Text] [Related]
35. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes.
Qi L; Liu S; Rifai N; Hunter D; Hu FB
Atherosclerosis; 2007 May; 192(1):204-10. PubMed ID: 16781717
[TBL] [Abstract][Full Text] [Related]
36. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.
Vaessen SF; Dallinga-Thie GM; Ross CJ; Splint LJ; Castellani LW; Rensen PC; Hayden MR; Schaap FG; Kuivenhoven JA
J Lipid Res; 2009 May; 50(5):880-4. PubMed ID: 19141870
[TBL] [Abstract][Full Text] [Related]
37. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.
Henneman P; Schaap FG; Havekes LM; Rensen PC; Frants RR; van Tol A; Hattori H; Smelt AH; van Dijk KW
Atherosclerosis; 2007 Jul; 193(1):129-34. PubMed ID: 16777114
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.
Shachter NS; Hayek T; Leff T; Smith JD; Rosenberg DW; Walsh A; Ramakrishnan R; Goldberg IJ; Ginsberg HN; Breslow JL
J Clin Invest; 1994 Apr; 93(4):1683-90. PubMed ID: 8163669
[TBL] [Abstract][Full Text] [Related]
39. Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice.
Chang CK; Lin XR; Lin YL; Fang WH; Lin SW; Chang SY; Kao JT
PLoS One; 2018; 13(2):e0192740. PubMed ID: 29425239
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto-Setälä K; Fisher EA; Chen X; Chajek-Shaul T; Hayek T; Zechner R; Walsh A; Ramakrishnan R; Ginsberg HN; Breslow JL
J Clin Invest; 1992 Nov; 90(5):1889-900. PubMed ID: 1430212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
